

medibio

Investor Update

March 2018



FORWARD LOOKING STATEMENTS

The purpose of the presentation is to provide an update of the business of Medibio Limited **(ASX:MEB) (OTCQB: MDBIF)**. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfillment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

**This presentation should not be relied on as a recommendation or forecast by Medibio Limited.
Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.**

The logo for medibio, featuring the word in a lowercase, sans-serif font. The letters 'me' are dark blue, 'di' are purple, and 'bio' are orange. The background consists of a pattern of small white dots arranged in a grid that tapers towards the center, creating a subtle circular effect.

medibio

The mental health technology and services company using objective physiologic data to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions.

MENTAL HEALTH REMAINS THE LARGEST HEALTHCARE MARKET IN THE WORLD

Mental illness is among the leading causes of ill-health and disability worldwide

- About **450 million** people in the world currently suffer from a mental health condition.
- **1 in 4 people** in the world will be affected by mental or neurologic disorders during their lifetime.
- Care-related costs are predicted to exceed an estimated **\$6 trillion by 2030.**
- Mental health is one of **the most pressing issues facing humankind.**

SOURCES: WHO, World health report.

**THE MEDIBIO MENTAL HEALTH PLATFORM:
EMPOWERING THE CARE JOURNEY**

From symptoms to successful outcomes, we provide objective measures and insights that empower caregivers and their patients.



A HISTORY OF PIONEERING RESEARCH

MENTAL ILLNESS AND BIOMARKERS IN THE HUMAN BODY

Physiology

Our approach exploits features of cardiovascular **physiology** influenced directly by the autonomic nervous system and susceptible to perturbation during sleep, as a source of biomarkers that correlate with onset and existence of mental dysfunction.

Data Science

+

Our **data science** approach focuses on deep learning AI to identify multiple mental health diseases via physiologic biomarkers and phenotypes.

23 + years
of data collected

A comprehensive patent suite

Circadian Heart Rate (CHR), technology, and diagnostics


BREAKTHROUGHS IN VISIBLE CIRCADIAN PATTERN DISTURBANCE OBSERVED VIA MONITORING DURING SLEEP

Insights from over 20 years of physiologic data research

Analysis of circadian heart rate (CHR) waveforms gives objective indications of physiological differences between different forms of mental illness such as anxiety, depression, and stress.

Mental state-linked autonomic nervous system disturbance (biological shifts) are observed during sleep when external influences are absent.

Distinctly different patterns are evident during sleep when confounding influences on heart rate are minimal.




INTRODUCING:

The Medibio Mental Health Technology Platform

A comprehensive product suite of consumer, corporate health, and professional care solutions featuring the world's first objective, biomarker-based measures in mental health.



ONE PLATFORM, MULTIPLE MARKETS




Built on a common technology platform, each product features unique features and capabilities by market.

THE MEDIBIO MENTAL HEALTH TECHNOLOGY PLATFORM


Mental **Insights**™

An **unregulated** product for self-managing mental health




Mental **Index**™

A **regulated** product for monitoring mental illness



Mental **Logics Professional Portal**™

A clinical decision support and data analysis platform.



REVENUE MODELS BY MARKET

CORPORATE HEALTH: Estimated Release Q4	
MENTAL INSIGHTS APP + HR PORTAL	
Initial Screening	\$20 per employee
Mental Insights Subscription	\$4.99 per employee, per month
Estimated Addressable Market	54 million US employees

CONSUMER: Estimated Release Q4, Q1 FY19		
	MHA CHECK-IN APP	MENTAL INSIGHTS
Cost Per Download	\$0	\$0
View Mental Insights Trending	Feature not available	\$4.99 per user, per month
Estimated Addressable Market	1 in 4 adults globally	1 in 4 adults globally

INTEGRATED HEALTH PLAN: Estimated Release Q1 FY19	
MENTAL INDEX APP + PROVIDER PORTAL	
Initial Exam Assessment	\$20 per patient
Mental Index Subscription	\$9.99 per patient, per month
Estimated Addressable Market	65.9 million US mental health visits a year

CORPORATE HEALTH

Providing objective analysis and complement of mental health care services to employers

Corporate health initiatives to focus on mental health and wellbeing of employees.

Businesses can now harness objective mental health measures to give employees a real time understanding of their own mental health.



Vital Conversations

Clients include:

pwc

Wesfarmers

CONSUMER OFFERING

EMPOWERING MENTAL HEALTH.

Through a simple connection to a wearable device, consumers and mental health patients alike will discover new insights into their mental health.

For the first time, people will track and objectively measure and manage their mental health.



Mental Insights™

INTEGRATED HEALTH CLINICAL WORKFLOW

- .01** Clinician prescribes Mental Index App
- .02** Wearable device collects CHR data from patient
- .03** Medibio app connects with device & data transmitted to HIPAA compliant Cloud
- .04** Data processed by machine learning algorithms in the Cloud
- .05** Clinician has secure access to results – anywhere / anytime

Mental **Index**TM
Mental Health Monitoring Solution

**FDA APPROVAL OF
MONITORING INDICATION**
—
Expected
Fall 2018

medibio Digital Mental Health Platform

Moderate
This score indicates that stress is having a Moderate impact on your body.

WHAT DOES THIS MEAN?

QUESTIONNAIRE

Q STRESS EFFLUX

THE DATA

MEASURE







TARGET

RESULT

MacBook

MAJOR STUDIES

ACCURACY



STUDY OUTLINE

DEPRESSION
Retrospective Study, 889 patients
November 2016

DEPRESSION
Retrospective Study, 26 patients
December 2016

**DEPRESSION, ANXIETY DISORDER,
SCHIZOPHRENIA**
Various studies

**SLEEP STAGING USING ECG
DATA**
7500 patients
June 2016

DEPRESSION
220 patients
July 2017

PTSD
48 patients
May 2017

PARTNER



PEER REVIEWED



MULTIPLE SITES



Versus 33-50% – Diagnostic accuracy in the Primary Care Setting¹
(1) Depression in Primary Care Vol 1: U.S. Department of Health

CORPORATE STRUCTURE

CAPITAL STRUCTURE (ASX:MEB) (OTCQB:MDBIF)

Market Cap

Share Price

Shares on Issue (per January 16, 2018 Appendix 3B)

\$52.1M

\$0.26

200.4M

Market Cap (fully diluted)

Share Price

Fully diluted shares (per January 16, 2018 Appendix 3B)


\$60.3M

\$0.26

232.0M

Cash Available

\$16.6M

10.6% 
FIDELITY (FIL)

5.4% 
CLAUDE SOLITARIO
Private holder

5.8% 
REGAL FUNDS MGMT
Institutional holder

4.9% 
IFM INVESTORS
Institutional holder

52.2% 
TOP 20

December 31, 2017 cash balance of \$15.1M plus \$1.5M anticipated inflow from stock option exercise and partly paid shares.

OPPORTUNITY SUMMARY

MEDIBIO DELIVERS:

A BETTER UNDERSTANDING OF MENTAL HEALTH

Traditional approaches to mental health care rely heavily on patient input and clinical judgement. Medibio to bring objective measures tracked and collected by physicians and their patients to provide a new, unbiased view of mental health.

EMPOWERED PRACTITIONER DECISION SUPPORT

Medibio to provide a comprehensive dashboard with multiple, objective data points facilitates decision making.

IMPROVED OUTCOMES

Medibio to unlock powerful applications in the diagnosis, treatment, and monitoring of mental health. Ultimately patients who have access to self-management tools are more likely to engage in their own health outcomes.



BOARD OF DIRECTORS



CHRIS INDERMAUR
Chairman



JACK COSENTINO
CEO/Managing Director



ANDREW MAXWELL
Non Executive Director



PATRICK KENNEDY
Former US Congressman
Founder, Kennedy Forum
Non Executive Director



DR FRANKLYN G PENDERGAST
Former member board of Trustee
and Board of Governors
Mayo Clinic and Medibio
Non-Executive Board Member



MICHAEL PHELPS
Non Executive Director




BRIAN MOWER
Chief Financial Officer



PETER CARLISLE
Managing Director, Olympics &
Action Sports, Octagon Worldwide

APPENDIX


CHR PATTERN ANALYSIS



INDIVIDUAL WITH **NORMAL BEHAVIORS**

- Sleep rates are visibly lower and less variable than awake rates.
- The onset of sleep and moment of waking show a clear change in the mean trend.
- Sleep and waking is usually brief and occurs quickly.
- Body movement data clearly correlates with heart rate, with a cessation of movement during the sleep period.


CHR PATTERN ANALYSIS



INDIVIDUAL WITH DEPRESSION

- The mean is within the normal range, but the sleep mean is slightly elevated.
- Rates fall to their lowest level shortly after the onset of sleep, and then rise progressively to awake values.
- This rising trend causes early waking, a common symptom of depression.
- Correlation between heart rate and body movement variable.

CHR PATTERN ANALYSIS



INDIVIDUAL WITH ANXIETY DISORDER

- Both the 24 hour and sleep means are moderately elevated.
- Rates are high at the onset of sleep due to sustained daytime physiological arousal.
- Heart rate declines to its lowest values an hour or two before waking.
- Morning rates are also elevated, accounting for acute morning anxiety that is often experienced by sufferers.

THANK YOU

Jack Cosentino

CEO and Managing Director

Jack.Consentino@Medibio.com.au

8696 Eagle Creek Circle, Savage, MN 55378